|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2007-11-12
|
|
pubmed:abstractText |
The purpose of this study was to evaluate the efficacy and toxicity of cisplatin, etoposide and irinotecan as first-line treatment in patients with extensive small-cell lung cancer (E-SCLC).
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Dec
|
|
pubmed:issn |
0169-5002
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
58
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
355-61
|
|
pubmed:meshHeading |
pubmed-meshheading:17698241-Adult,
pubmed-meshheading:17698241-Aged,
pubmed-meshheading:17698241-Camptothecin,
pubmed-meshheading:17698241-Carcinoma, Small Cell,
pubmed-meshheading:17698241-Cisplatin,
pubmed-meshheading:17698241-Disease Progression,
pubmed-meshheading:17698241-Dose-Response Relationship, Drug,
pubmed-meshheading:17698241-Drug Therapy, Combination,
pubmed-meshheading:17698241-Etoposide,
pubmed-meshheading:17698241-Female,
pubmed-meshheading:17698241-Humans,
pubmed-meshheading:17698241-Lung Neoplasms,
pubmed-meshheading:17698241-Male,
pubmed-meshheading:17698241-Middle Aged,
pubmed-meshheading:17698241-Survival Rate
|
|
pubmed:year |
2007
|
|
pubmed:articleTitle |
Combination chemotherapy with cisplatin, etoposide and irinotecan in patients with extensive small-cell lung cancer: A phase II study of the Hellenic Co-operative Oncology Group.
|
|
pubmed:affiliation |
Second Department of Internal Medicine-Propaedeutic, Oncology Section, University General Hospital Attikon, Athens, Greece. hecogoff@otenet.gr
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial, Phase II
|
